Campral Clears FDA For Alcohol Dependence: Renal Study Part Of Phase IV
Executive Summary
Merck KGaA subsidiary Lipha will determine appropriate Campral dosing in patients with severe renal impairment as a postmarketing commitment following FDA approval of the alcoholism therapy
You may also be interested in...
Forest Launches Combunox And Campral Without Adding Sales Reps
Forest's Combunox and Campral launches do not necessitate an expansion of the sales force at this time, President Kenneth Goodman said April 19 during an investor call
Forest Launches Combunox And Campral Without Adding Sales Reps
Forest's Combunox and Campral launches do not necessitate an expansion of the sales force at this time, President Kenneth Goodman said April 19 during an investor call
Forest/Lipha Campral
FDA approves Campral (acamprosate) July 29 for the treatment of "alcohol dependent individuals seeking to continue to remain alcohol-free after they have stopped drinking." Campral should be used as one part of a comprehensive alcoholism management program that includes "psychosocial support," FDA says in a July 29 "Talk Paper." Forest will launch the drug in the U.S. near the end of the year...